Diaporama
You are here :
  1. The firm
  2. RebrAIn raises 3.7 million euros to support the fight against Parkinson's disease
RebrAIn raises 3.7 million euros to support the fight against Parkinson's disease

RebrAIn raises 3.7 million euros to support the fight against Parkinson's disease

Published on : 05/04/2024 05 April Apr 04 2024
Deals EN

Altaïr Avocats advised RebrAIn, a Bordeaux-based medtech company, in their €3.7 million fundraising. Founded in 2021, RebrAIn has developed a solution aimed at simplifying electrode placement in the brain for patients suffering from Parkinson's disease or tremors.

The Bordeaux-based medtech RebrAIn, incubated at Chrysa-link and led by David Caumartin, Emmanuel Cuny, and Nejib Zemzemi, has developed an innovative technology based on artificial intelligence to improve Deep Brain Stimulation (DBS), a surgical intervention used notably to treat Parkinson's disease.

Through a precise targeting method and a collaborative health data registry, this technology aims to simplify, standardize, and make DBS more accessible, which, until now, has only been used by 3% of eligible patients worldwide.

RebrAIn has completed a €3.7 million Seed funding round, led by Karista and supported by Nouvelle Aquitaine CO-Investment (NACO), a significant milestone for RebrAIn.

RebrAIn aims to accelerate its commercial development internationally, particularly in the United States, and to intensify its R&D efforts. The funds will also be used to expand RebrAIn's team, with the recruitment of data scientists and sales personnel.
 

The parties involved in this transaction:


Altaïr Avocats supported RebrAIn on its corporate aspects with Sébastien Péronne, partner Marie Elgart, and Aude Idris, associates, complemented by the support of the IP/IT team composed of Christophe Héry, partner, and Albane Watine, associate.

 
Share on
Publish this article Share on LinkedIn Share on Facebook Send by E-mail

History

<< < 1 2 3 4 5 6 7 ... > >>